Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative gait and balance parameters.
Each subject will be randomized 1:1 to one of the following sequences:
Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late treatment period
Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late treatment period
Treatment A = RVT-101 35 mg once daily.
Treatment B = Placebo once daily.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence AB | Other | RVT-101 35 mg in Period II and Placebo in Period IV |
|
| Sequence BA | Other | Placebo in Period II and RVT-101 35 mg in Period IV |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RVT-101 35 mg | Drug | RVT-101 once daily, oral, 35-mg tablets |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools. | Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period | Baseline, 2 weeks |
| Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools. | Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under dual task trial condition (meaning walking while performing another task) at the end of each two-week treatment period. | Baseline, 2 weeks |
Not provided
Not provided
Key Inclusion Criteria:
Male or female subject with a clinical diagnosis of Alzheimer's disease (AD), dementia with Lewy bodies (DLB), or Parkinson's disease dementia (PDD).
Mini Mental State Examination score 14 to 26 Gait impairment, as assessed by history gathered by the clinical investigator and quantitative measurements Subjects must be on stable background acetylcholinesterase inhibitor therapy
Key Exclusion Criteria:
History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia (in the opinion of the investigator) Any clinically relevant concomitant disease which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ilise Lombardo, MD | Axovant Sciences, Inc., Senior VP Clinical Research | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| US101 | Phoenix | Arizona | 85013 | United States | ||
| US118 |
68 participants signed consent and were screened for participation. Of these, 40 entered a 2-week single-blind placebo run-in period with treatment with placebo qd. Subjects were allowed to re-screen if they failed the initial screening assessments. All subjects deemed eligible following run-in were randomized to a treatment group.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sequence 1: AB | RVT-101 35 mg: once daily, oral, 35-mg tablets in Period II Placebo in Period IV |
| FG001 | Sequence 2: BA | Placebo: once daily, oral, matching tablets in Period II RVT-101 35 mg: once daily, oral, 35-mg tablets in Period IV |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 7, 2017 | Nov 21, 2018 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo once daily, oral |
|
| Simi Valley |
| California |
| 93065 |
| United States |
| US117 | Temecula | California | 92591 | United States |
| US115 | Boca Raton | Florida | 33431 | United States |
| US109 | Hallandale | Florida | 33009 | United States |
| US116 | Miami | Florida | 33137 | United States |
| US108 | Pensacola | Florida | 32502 | United States |
| US106 | Columbus | Georgia | 31909 | United States |
| US107 | Indianapolis | Indiana | 46202 | United States |
| US102 | Ann Arbor | Michigan | 48106 | United States |
| US111 | Columbus | Ohio | 43210 | United States |
| Safety Population | The Safety population included subjects who took at least 1 dose of double-blind study drug |
|
| Intent to Treat (ITT) Population | Subjects took at least 1 dose of DB study drug and had at least 1 post-baseline assessment |
|
| Per-Protocol Population | Subjects in the ITT population who had no major protocol violations |
|
| COMPLETED | Subjects in the ITT population who completed the study |
|
| NOT COMPLETED |
|
Safety Population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sequence 1: AB | RVT-101 35 mg: once daily, oral, 35-mg tablets in Period II Placebo in Period IV |
| BG001 | Sequence 2: BA | Placebo: once daily, oral, matching tablets in Period II RVT-101 35 mg: once daily, oral, 35-mg tablets in Period IV |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Full Range | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| BMI | Mean | Full Range | kg/m^2 |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools. | Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period | ITT Population | Posted | Least Squares Mean | Standard Error | cm/sec | Baseline, 2 weeks |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools. | Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under dual task trial condition (meaning walking while performing another task) at the end of each two-week treatment period. | ITT Population | Posted | Least Squares Mean | Standard Error | cm/sec | Baseline, 2 weeks |
|
|
Screening through post-treatment (Up to 16 Weeks)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | RVT-101 35 mg | Subjects who dosed with RVT-101 in both sequences (AB and BA) are included | 0 | 38 | 0 | 38 | 0 | 38 |
| EG001 | Placebo | Subjects who dosed with Placebo in both sequences (AB and BA) are included | 0 | 38 | 0 | 38 | 0 | 38 |
| EG002 | Screening Period | Participants screened (0-4 weeks) prior to entering to the first dose of single-blind study medication (ie, prior to the Run-In period) | 0 | 68 | 0 | 68 | 0 | 68 |
| EG003 | Run-In Period | Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet (for 2 weeks) | 0 | 40 | 0 | 40 | 0 | 40 |
| EG004 | RVT-101 Post-Treatment | Subjects reported adverse events after completing the treatment period. The Post-Treatment period - defined as up to 17 days post-last-dose | 0 | 38 | 0 | 38 | 0 | 38 |
| EG005 | Placebo Post-Treatment | Subjects reported adverse events after completing the treatment period. The Post-Treatment period - defined as up to 17 days post-last-dose | 0 | 38 | 0 | 38 | 0 | 38 |
Not provided
Not provided
All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director, Clinical Development | Axovant Sciences, Inc. | 1-833-296-8268 | clinicaltrials@axovant.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Nov 29, 2017 | Nov 30, 2018 | SAP_001.pdf |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D020961 | Lewy Body Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| C548140 | 3-benzenesulfonyl-8-piperazin-1-ylquinoline |
Not provided
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|